{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:13:25Z","timestamp":1790230405969,"version":"4.1.0"},"reference-count":83,"publisher":"Informa UK Limited","issue":"8","funder":[{"DOI":"10.13039\/100006483","name":"Abbvie","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Gilead"},{"name":"Janssen"},{"name":"Roche"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2018,4,30]]},"DOI":"10.2217\/fon-2017-0466","type":"journal-article","created":{"date-parts":[[2017,12,15]],"date-time":"2017-12-15T16:16:24Z","timestamp":1513354584000},"page":"681-697","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Ibrutinib and its use in the Treatment of Chronic Lymphocytic Leukemia"],"prefix":"10.1080","volume":"14","author":[{"given":"Anna Maria","family":"Frustaci","sequence":"first","affiliation":[{"name":"Dept of Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano, Piazza Ospedale Maggiore 3, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Tedeschi","sequence":"additional","affiliation":[{"name":"Dept of Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano, Piazza Ospedale Maggiore 3, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Deodato","sequence":"additional","affiliation":[{"name":"Dept of Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano, Piazza Ospedale Maggiore 3, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Mazzucchelli","sequence":"additional","affiliation":[{"name":"Dept of Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano, Piazza Ospedale Maggiore 3, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Cairoli","sequence":"additional","affiliation":[{"name":"Dept of Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano, Piazza Ospedale Maggiore 3, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Montillo","sequence":"additional","affiliation":[{"name":"Dept of Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano, Piazza Ospedale Maggiore 3, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2017,12,15]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-651125"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-09-667675"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-05-647925"},{"key":"e_1_3_2_6_1","unstructured":"US FDA approves IMBRUVICA \u00ae (ibrutinib) for first-line treatment of chronic lymphocytic leukemia. Press release March 4 2016.www.investor.jnj.com\/releasedetail.cfm?releaseid=\u201c958950\u201d."},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2009.72"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri955"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.21.120601.141018"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2016.1191943"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-328484"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.7906"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215637"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1004594107"},{"key":"e_1_3_2_15_1","volume-title":"59th ASH Meeting","author":"Rozovski U","year":"2016","unstructured":"Rozovski U , HarrisDM, LiPet al. Ibrutinib disrupts the metabolic program of CLL cells in vivo. Presented at: 59th ASH Meeting. San Diego, CA, USA, 9\u201312 December 2016."},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-507947"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.11951"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-06-583294"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-233692"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-606038"},{"key":"e_1_3_2_21_1","volume-title":"59th ASH Meeting","author":"O\u2019Brien S","year":"2016","unstructured":"O\u2019Brien S , FurmanRR, CoutreSEet al. Five-year experience with single-agent ibrutinib in patients with previously untreated and relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic leukemia. Presented at: 59th ASH Meeting. San Diego, CA, USA, 9\u201312 December 2016."},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71182-9"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30212-1"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400376"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.175"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-527853"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2017.1264387"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70335-3"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-617522"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-585869"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00465-9"},{"key":"e_1_3_2_32_1","volume-title":"52th ASCO Meeting","author":"Fraser G","year":"2016","unstructured":"Fraser G , CramerP, DemirkanFet al. Ibrutinib (I) plus bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): a 2-year follow-up of the HELIOS study. Presented at: 52th ASCO Meeting. Chicago, IL, USA, 3\u20137 June 2016."},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70513-8"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388"},{"key":"e_1_3_2_35_1","volume-title":"59th ASH Meeting","author":"Barr P","year":"2016","unstructured":"Barr P , RobakT, OwenCJet al. Updated efficacy and safety from the Phase III Resonate-2 study: ibrutinib as first-line treatment option in patients 65 years and older with chronic lymphocytic leukemia\/small lymphocytic leukemia. Presented at: 59th ASH Meeting. San Diego, CA, USA, 9\u201312 December 2016."},{"key":"e_1_3_2_36_1","volume-title":"58th ASH Meeting","author":"Parikh SA","year":"2015","unstructured":"Parikh SA , ChaffeeKR, CallTGet al. Ibrutinib therapy for chronic lymphocytic leukemia (CLL): an analysis of a large cohort of patients treated in routine clinical practice. Presented at: 58th ASH Meeting. Orlando, FL, USA, 5\u20138 December 2015."},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.144576"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.147900"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1292353"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24773"},{"key":"e_1_3_2_41_1","volume-title":"59th ASH Meeting","author":"Mato AR","year":"2016","unstructured":"Mato AR , LamannaN, UjjaniCSet al. Toxicities and outcomes of ibrutinib-treated patients in the USA: large retrospective analysis of 621 real-world patients. Presented at: 59th ASH Meeting. San Diego, CA, USA, 9\u201312 December 2016."},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.247"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.3229.3229"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.4387.4387"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-604272"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-712828"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx031"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14324"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.164103"},{"issue":"11","key":"e_1_3_2_50_1","first-page":"970","article-title":"Proposed algorithm for managing ibrutinib-related atrial fibrillation","volume":"30","author":"Vrontikis A","year":"2016","unstructured":"Vrontikis A , CareyJ, GilreathJAet al. Proposed algorithm for managing ibrutinib-related atrial fibrillation. Oncology30(11), 970\u2013974 (2016).","journal-title":"Oncology"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw210"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2014.218"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1402716"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400029"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29566"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11589"},{"key":"e_1_3_2_57_1","volume-title":"58th ASH Meeting","author":"Cosson A","year":"2015","unstructured":"Cosson A , ChapiroE, LambertJet al. Presented at: 58th ASH Meeting. Orlando, FL, USA, 5\u20138 December 2015."},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3061-3"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315226"},{"key":"e_1_3_2_60_1","unstructured":"Gilead Sciences Inc.\n. Written Communication. 11 March 2016."},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509981"},{"key":"e_1_3_2_62_1","volume-title":"59th ASH Meeting","author":"Awan FT","year":"2016","unstructured":"Awan FT , SchuhA, BrownJRet al. Acalabrutinib monotherapy in patients with ibrutinib intolerance: results from the Phase I\/II ACE-CL-001 clinical study. Presented at: 59th ASH Meeting. San Diego, CA, USA, 9\u201312 December 2016."},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-664086"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-02-765115"},{"key":"e_1_3_2_65_1","volume-title":"58th ASH Meeting","author":"Tam C","year":"2015","unstructured":"Tam C , GriggAP, OpatSet al. The BTK inhibitor, BGB-3111, is safe, tolerable and highly active in patients with relapsed\/refractory B-cell malignancies: initial report of a Phase I first-in-human trial. Presented at: 58th ASH Meeting. Orlando, FL, USA, 5\u20138 December 2015."},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3048"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1513257"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30019-5"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-603670"},{"key":"e_1_3_2_70_1","volume-title":"52nd ASCO Meeting","author":"Jones JA","year":"2016","unstructured":"Jones JA , WierdaWG, ChoiMYet al. Venetoclax activity in CLL patients who have relapsed after or are refractory to ibrutinib or idelalisib. Presented at: 52nd ASCO Meeting. Chicago, IL, USA, 3\u20137 June 2016."},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-772285"},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2349"},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24660"},{"key":"e_1_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.2009"},{"key":"e_1_3_2_75_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-547869"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.107011"},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1201567"},{"key":"e_1_3_2_78_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.708.708"},{"key":"e_1_3_2_79_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2016.155"},{"key":"e_1_3_2_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2014.08.2198"},{"key":"e_1_3_2_81_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1251592"},{"key":"e_1_3_2_82_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-12-737346"},{"key":"e_1_3_2_83_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14540"},{"key":"e_1_3_2_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.09.013"},{"key":"e_1_3_2_85_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2013.1.138"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2017-0466","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:45:43Z","timestamp":1719125143000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2017-0466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,15]]},"references-count":83,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,4,30]]}},"alternative-id":["10.2217\/fon-2017-0466"],"URL":"https:\/\/doi.org\/10.2217\/fon-2017-0466","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,15]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2017-09-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-11-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-12-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}